Granules India gets USFDA nod for generic drug

 17 Dec 2024 04:32 PM

Granules Pharmaceuticals, Inc. secured USFDA approval for generic Lisdexamfetamine Dimesylate chewable tablets. The tablets treat ADHD in children and adults. They also treat binge eating disorder in adults. The drug is available in various strengths. This approval addresses drug shortages. Granules India's chairman emphasized their commitment to patient needs.

GRANULES INDIA: CO ANNOUNCES FDA APPROVAL FOR ADHD TREATMENT, ADDRESSING DRUG SHORTAGES IN THE U.S.

 17 Dec 2024 11:07 AM

GRANULES INDIA: CO ANNOUNCES FDA APPROVAL FOR ADHD TREATMENT, ADDRESSING DRUG SHORTAGES IN THE U.S.

F&O Ban List: PVR Inox, RBL Bank among 6 stocks under trade ban on Friday

 13 Dec 2024 07:40 AM

Six stocks, including Granules India, Hindustan Copper, and PVR Inox, were under F&O trade ban on Friday due to high open interest exceeding market-wide position limits. Nifty and Sensex closed lower on Thursday, impacted by selling in bank, auto, and FMCG sectors.

Buy Granules India, target price Rs 625: Motilal Oswal Securities

 05 Dec 2024 09:31 AM

Motilal Oswal Securities has recommended buying shares of Granules India Ltd. with a target price of Rs 625. Currently priced at Rs 535.45, Granules India aims to achieve 29% earnings CAGR over FY25-27. The regulatory inspection at Gagillapur poses short-term challenges but remediation measures are underway. Promoters hold 38.87% stake, while FIIs own 19.49%.

Gainers & Losers: Adani Ports, Varun Beverages among 5 stocks that moved most on Tuesday

 03 Dec 2024 05:14 PM

Indian stocks ended higher with HDFC Bank and Reliance Industries leading. Niva Bupa shares surged 10.75%, while Granules India stocks fell 10% due to US FDA issues. Other notable movers include Adani Ports and Varun Beverages.

AUROBINDO PHARMA: CO IS BIGGEST BENEFICIARY OF GRANULES SETBACK - INVESTEC REPORT

 03 Dec 2024 03:08 PM

AUROBINDO PHARMA: CO IS BIGGEST BENEFICIARY OF GRANULES SETBACK - INVESTEC REPORT

GRANULES: GAGILLAPUR FACILITY IS CRUCIAL TO THE COMPANY'S OPERATIONS, CONTRIBUTING OVER 70% OF OVERALL REVENUE AS OF THE JUNE QUARTER

 03 Dec 2024 02:37 PM

GRANULES: GAGILLAPUR FACILITY IS CRUCIAL TO THE COMPANY'S OPERATIONS, CONTRIBUTING OVER 70% OF OVERALL REVENUE AS OF THE JUNE QUARTER

GRANULES INDIA LTD: CO US FDA HAS CLASSIFIED THE INSPECTION AS “OFFICIAL ACTION INDICATED” (OAI) || CO HAS RESPONDED TO ALL THE OBSERVATIONS ISSUED BY THE US FDA

 03 Dec 2024 02:31 PM

GRANULES INDIA LTD: CO US FDA HAS CLASSIFIED THE INSPECTION AS “OFFICIAL ACTION INDICATED” (OAI) || CO HAS RESPONDED TO ALL THE OBSERVATIONS ISSUED BY THE US FDA

GRANULES INDIA: CO HAS RESPONDED TO ALL THE OBSERVATIONS ISSUED BY THE US FDA

 03 Dec 2024 02:30 PM

GRANULES INDIA: CO HAS RESPONDED TO ALL THE OBSERVATIONS ISSUED BY THE US FDA

GRANULES: CO NET ZERO COMMITMENT VALIDATED AND APPROVED BY SCIENCE BASED TARGETS INITIATIVE

 27 Nov 2024 11:48 AM

GRANULES: CO NET ZERO COMMITMENT VALIDATED AND APPROVED BY SCIENCE BASED TARGETS INITIATIVE